SCHEMBL2400977

SCHEMBL2400977

O=C(NCCCc1ccccc1)C1=NOC2(CCN(S(=O)(=O)c3ccc(F)cc3)CC2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TGM2 P21980 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PKM P14618 2/20 0.43
POLB P06746 1/20 0.43
EPHX2 P34913 1/20 0.42
GAA P10253 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413110 0.85 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2TGM2NPC1RAB9A
SCHEMBL2401367 0.83 TSHR (0.46) ALDH1A1SMN1; SMN2TGM2GAAMEN1
SCHEMBL2402458 0.83 PKM (0.53) ALDH1A1SMN1; SMN2NPC1PKMPOLB
SCHEMBL2401326 0.82 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2POLBGAAMEN1
SCHEMBL2401315 0.82 NAMPT (0.52) ALDH1A1PKMPOLBGAAMEN1
SCHEMBL2581274 0.82 F13A1 (0.46) ALDH1A1SMN1; SMN2TGM2PKMGAA
SCHEMBL2400878 0.81 CYP1A2 (0.57) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL6409630 0.80 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2PKMPOLBGAA
SCHEMBL2580957 0.79 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2POLBGAAMEN1
SCHEMBL2403146 0.79 CYP2C19 (0.43) ALDH1A1SMN1; SMN2RAB9AGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 ALDH1A1 156/4885SMN1; SMN2 1407/4885TGM2 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.